Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 4, 2014, Pages 393-398

  Weller, Stephen ^a   Chen, Shuguang ^a   Borland, Julie ^a   Savina, Paul ^a   Wynne, Brian ^a   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE; DOLUTEGRAVIR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET; VOMITING;

ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; DIDEOXYNUCLEOSIDES; DIETARY FATS; DRUG COMBINATIONS; FEMALE; FOOD-DRUG INTERACTIONS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LAMIVUDINE; MALE; THERAPEUTIC EQUIVALENCY; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 84903776448     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000193     Document Type: Article

References (25)

1. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11-19
2. Permpalung N, Putcharoen O, Avihingsanon A, et al. Treatment of HIV infection with once-daily regimens. Expert Opin Pharmacother. 2012; 13:2301-2317
3. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17:169-177. (Pubitemid 36444006)
4. Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. Clin Infect Dis. 2005;41(suppl 4):S239-S246. (Pubitemid 41099618)
5. Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14:168-178
6. Tivicay [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2013
7. Castellino S, Moss L, Wagner D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57:3536-3546
8. Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41:353-361
9. Hightower KE, Wang R, DeAnda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55:4552-4559
10. Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7:390-400
11. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54:254-258
12. Epzicom [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2012
13. Mallal S, Phillips E, Carosi G, et al. HLA-B5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579. (Pubitemid 351214284)
14. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: food-effect bioavailability and fed bioequivalence studies, December 2002. Available at: http://www.fda.gov/downloads/regulatoryinformation/guidances/ ucm126833.pdf. Accessed March 19, 2014
15. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations, March 2003. Available at: http://www.fda.gov/ downloads/Drugs/./Guidances/ucm070124.pdf. Accessed March 19, 2014
16. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56:1627-1629
17. Yuen GJ, Lou Y, Thompson NF, et al. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol. 2001;41:277-288. (Pubitemid 32184980)
18. Baker K, Lou Y, Yuen GJ, et al. The bioequivalence and effect of food of a new once-a-day fixed dose combination tablet of abacavir (ABC) and lamivudine (3TC). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 4, 2004;Washington, DC
19. Chittick GE, Gillotin C, McDowell JA, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy. 1999;19:932-942. (Pubitemid 29377311)
20. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47:351-371. (Pubitemid 351685386)
21. Johnson MA, Moore KH, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-66. (Pubitemid 29056000)
22. Walmsley SL, Antela A, Clumeck N, et al; for the SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807-1818
23. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927-935
24. Feinberg J, Clotet B, Khuong M-A, et al. Once-daily dolutegravir (DTG) is superior to darunavir/ritonavir (DRV/r) in antiretroviralnaive adults: 48 week results from FLAMINGO (ING114915) [H-1464a]. Presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO.
25. Mitra A, Wu Y. Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. AAPS J. 2012;14: 646-655